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MaBACKGROUND Injury due to myocardial infarction (MI) is largely irreversible. Once an infarct has occurred, the clinical
goal becomes limiting remodeling, preserving left ventricular function, and preventing heart failure. Although traditional
approaches (e.g., b-blockers) partially preserve left ventricular function, novel strategies are needed to limit ventricular
remodeling post-MI.
OBJECTIVES The aim of this study was to determine the role of glycogen synthase kinase–3a (GSK-3a) in post-MI
remodeling.
METHODS Mice with cardiomyocyte-speciﬁc conditional deletion of Gsk3a and littermate controls underwent sham
or MI surgery. Heart function was assessed using serial M-mode echocardiography.
RESULTS Gsk3a deletion in the heart markedly limits remodeling and preserves left ventricular function post-MI.
This is due at least in part to dramatic thinning and expansion of the scar in the control hearts, which was less in the heart
of knockout (KO) mice. In contrast, the border zone in the KO mice demonstrated a much thicker scar, and thereweremore
viable cardiomyocytes within the scar/border zone. This was associated with less apoptosis and more proliferation
of cardiomyocytes in the KO mice. Mechanistically, reduced apoptosis was due, at least in part, to a marked decrease in
the Bax/Bcl-2 ratio, and increased cardiomyocyte proliferation was mediated through cyclin E1 and E2F-1 in the hearts of
the KO mice.
CONCLUSIONS Taken together, these ﬁndings show that reducing GSK-3a expression in cardiomyocytes limits
ventricular remodeling and preserves cardiac function post-MI. Speciﬁcally targeting GSK-3a could be a novel strategy
to limit adverse remodeling and heart failure. (J Am Coll Cardiol 2014;64:696–706) © 2014 by the American College of
Cardiology Foundation.M yocardial infarction (MI) and its sequelae,in particular heart failure, are the leadingcauses of death in the developed world
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ABB R E V I A T I O N S
AND ACRONYMS
BrdU = 5-bromo-20-
deoxyuridine
GSK = glycogen synthase
kinase
Gsk3aﬂ/ﬂ = homozygous Gsk3a
ﬂoxed mouse
Gsk3aﬂ/ﬂ Cre = homozygous
Gsk3a ﬂoxed mouse with
heterozygous Mer-Cre-Mer
KO = knockout
LV = left ventricular
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697importantly ischemic injury, can lead to progressive
cardiomyocyte loss. Apoptosis is uncommon in the
normal heart but is frequently seen in the ischemic
heart (5). The endogenous regenerative capacity of
the heart appears insufﬁcient to replenish lost myo-
cytes, so even relatively low levels of apoptosis can
have profound effects on cardiac function (5). This
has necessitated the use of strategies such as the in-
jection of stem or progenitor cells into the infarcted
region (6). Although these strategies hold promise,
the activation of endogenous repair mechanisms
within the heart could, in theory, represent a superior
strategy.SEE PAGE 707
MI = myocardial infarction
Rb = retinoblastoma protein
Tam = tamoxifen
TUNEL = terminal
deoxynucleotidyl transferase
dUTP nick end labeling
WT = wild-typeGlycogen synthase kinase (GSK)–3b has been well
studied in various pathophysiological conditions (7–
11), but the role of GSK-3a in various pathologic set-
tings, including ischemic injury and heart failure, is
still poorly understood. This bias toward GSK-3b
arose from early reports using Drosophila that
concluded that GSK-3b was the dominant isoform
because it was better able to rescue Wnt/wingless
pathway defects (12,13). This bias appears to remain,
with many more publications focusing on GSK-3b
than on GSK-3a. To summarize, although the roles
of GSK-3a remain unclear in many settings, it is clear
that there are unique, overlapping functions of the 2
isoforms. In short, despite the 97% sequence simi-
larity, these kinase have many nonoverlapping roles.
Global deletion of Gsk3a is detrimental in the
setting of stress, leading to deterioration in
cardiac function and increased hypertrophy, cardiac
ﬁbrosis, and ventricular remodeling (14,15). Surpris-
ingly, a similar phenotype of heart failure and
hypertrophy has been reported with a constitutively
active (S21A mutant) Gsk3a global knock-in mouse
when challenged with pressure overload (16).
Furthermore, cardiac-speciﬁc overexpression of GSK-
3a via transgenesis attenuates cardiac hypertrophy
and increases ﬁbrosis and apoptosis post transverse
aortic constriction (17,18). These observations, from 3
different models, have led to uncertainty as to the
roles of GSK-3a in the pathophysiology of heart
failure. Moreover, global knockout (KO) or knock-in
models can lead to compensatory effects that
complicate the interpretation of phenotypes (19) and
rarely, if ever, recapitulate the conditional gene
deletion, for a variety of reasons.
Herein, for the ﬁrst time, we use a cardiomyocyte-
speciﬁc conditional KO mouse to characterize the
rather surprising roles of GSK-3a in regulating the
consequences of MI. We report that conditionaldeletion of GSK-3a leads to marked protec-
tion post-MI that is due to less cardiomyocyte
death, less scar expansion and thinning, and
increased cardiomyocyte proliferation in the
KO hearts, the latter being driven by alter-
ations in the activity of cell-cycle regulators.
We believe that these studies will bring more
clarity to the true roles played by GSK-3a in
the infarcted heart.
METHODS
A detailed method is supplied in the Online
Appendix.
MICE. The Gsk3aﬂox/ﬂox (ﬂ/ﬂ) mouse was
generated as previously described (8). Mice
expressing a-myosin heavy chain promoter-
driven, tamoxifen (Tam)–inducible heterozy-
gous Mer-Cre-Mer (a gift from Dr. J.
Molkentin, Cincinnati Children’s Hospital,
Cincinnati, Ohio) were crossed for 2 generations with
Gsk3aﬂ/ﬂ mice to generate Gsk3aﬂ/ﬂ Cre mice. Both
mouse strains were on the C57BL/6 background. At
12 weeks of age, when physiological development
is largely complete, all male mice were placed on a
Tam chow diet (400 mg/kg) for 15 days, followed by
regular chow for an additional 15 days (to allow the
clearance of Tam from the mice). Gsk3aﬂ/ﬂ/ Creþ/ /Tam
mice were conditional KO, whereas littermates
Gsk3aﬂ/ﬂ/Tam represented controls (wild-type [WT]).
The Institutional Animal Care and Use Committee of
Temple University approved all animal procedures
and treatments.
ANTIBODIES. A detailed antibody list and applica-
tion is supplied in the Online Appendix.
MI. After baseline echocardiography, permanent oc-
clusion of the proximal left anterior descending
coronary artery, or sham surgery, was performed in
WT versus KO male littermates, as described previ-
ously (20). After the 8-week echocardiographic ex-
amination, the mice were euthanized for different
studies.
ECHOCARDIOGRAPHY. Echocardiography was per-
formed as described previously (15). In brief,
transthoracic 2-dimensional motion-mode echocar-
diography was performed at 0, 1, 2, 4, and 8 weeks
post-MI with a 12-MHz probe (VisualSonics, Tor-
onto, ON, Canada) on mice anesthetized by inhala-
tion of isoﬂurane (1.0% to 1.5%). Left ventricular
(LV) end-systolic interior dimension, end-diastolic
interior dimension, ejection fraction, and fractional
shortening values were analyzed using the Vevo770
program (VisualSonics).
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FIGURE 1 GSK-3a Activity in Ischemic Heart and Characterization of Conditional Gsk3a KO Mice
(A) Immunoblot of sham and 3-week post–myocardial infarction (MI) left ventricular (LV) lysates and quantiﬁcation (B) show signiﬁcantly
increased phosphorylation (inhibition) of glycogen synthase kinase (GSK)–3a at Ser21 post-MI. (C) GSK-3a and GSK-3b protein expression
was analyzed by immunoblotting of LV lysates. Immunoblot panel shows protein expression in knockout (KO) and littermate controls
(n ¼ 13 for each group). (D) Immunoblot quantiﬁcation conﬁrms an 88.5%  6.2% reduction of GSK-3a expression in KO versus wild-type
(WT) mice. GSK-3b expression was unchanged. (E) Immunoblotting using 3-week post-MI LV lysates and (F) blot quantiﬁcation show
comparable phosphorylation of GSK-3b in WT and KO mice post-MI. n ¼ 4 to 5 for WT and KO mice. Data are presented as mean  SEM.
**p < 0.01.
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698HISTOCHEMISTRY AND IMMUNOHISTOCHEMISTRY.
A detailed protocol is provided in the Online
Appendix. In brief, 3 and 8 weeks post-MI, the whole
heart was excised from anesthetized mice and ﬁxed in
4% paraformaldehyde, dehydrated through increasing
concentrations of ethanol, and then embedded in
parafﬁn (9). Heart sections (5 mm) were stained
using Masson’s trichrome (Sigma-Aldrich, St. Louis,
Missouri) or immunoﬂuorescence antibodies. A Nikon
Eclipse 80i ﬂuorescent microscope and NIS Elements
software (Nikon Corporation, Tokyo, Japan) were used
to capture the images and analysis.STATISTICAL ANALYSIS. Differences between data
groups were evaluated for signiﬁcance using unpaired
Student t test (GraphPad Prism, GraphPad Software,
San Diego, California). Data are expressed as mean 
SEM. For all tests, p values <0.05 were considered to
indicate statistical signiﬁcance.
RESULTS
To test our hypothesis that GSK-3a plays a critical
role in MI-induced remodeling, we ﬁrst determined
the effect of ischemic injury on GSK-3a activity, as
76
5
4
0 2 4 6 8 10
Time (Week)
LV
ID
;d
 (m
m
)
7
6
5
4
3
0 2 4 6 8 10
Time (Week)
LV
ID
;s
 (m
m
)
40
30
20
10
0
0 2 4 6 8 10
Time (Week)
LV
FS
 %
80
60
40
20
0
0 2 4 6 8 10
Time (Week)
LV
EF
 %
**
**
** **
**** ******
Gsk3αfl/fl Gsk3αfl/fl Sham
Sham
MI
Gsk3αfl/fl Cre Gsk3αfl/fl Cre MI
A B
C D
FIGURE 2 Deletion of Gsk3a Preserves Post-MI Cardiac Function and
Limits LV Remodeling
After myocardial infarction (MI) or sham surgery, cardiac function was assessed by
transthoracic 2-dimensional M-mode echocardiography at various time points as shown,
over a period of 8 weeks. Left ventricular (LV) end-diastolic dimension (LVIDD) (A) and LV
end-systolic dimension (LVIDS) (B) were signiﬁcantly less in the knockout (KO) mice at
4 and 8 weeks post-MI. (C) LV ejection fraction and (D) LV fractional shortening were
signiﬁcantly greater in the KO mice at 4 and 8 weeks post-MI. n ¼ 16 to 22 for MI group
and n ¼ 4 for sham group. Values are presented as mean  SEM, and p values shown are
for the comparison between wild-type (WT) and KO mice subjected to MI. **p < 0.01;
***p < 0.001.
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699assessed by phosphorylation. WT mice were sub-
jected to MI surgery, and 3 weeks later, LV lysates
were analyzed for GSK-3a phosphorylation (on
Ser21). Phosphorylation of GSK-3a was signiﬁcantly
increased, conﬁrming that chronic MI leads to inhi-
bition of GSK-3a (Figs. 1A and 1B, Online Figs. 1A
and 1B). Therefore, we asked if GSK-3a might have
a role in MI-induced ventricular remodeling. We
used the Tam-inducible Mer-Cre-Mer system to
delete Gsk3a speciﬁcally in cardiomyocytes. The
progeny were viable, fertile, and showed no overt
pathologic phenotype. After Tam treatment, expres-
sion levels of GSK-3a and GSK-3b were determined
by immunoblotting. GSK-3a protein expression in
the KO mice was reduced to 12% of baseline, and
GSK-3b expression and activity were comparable
(Figs. 1C to 1F).
DELETION OF Gsk3a LIMITS POST-MI CARDIAC
REMODELING AND PRESERVES CONTRACTILE
FUNCTION. Gsk3a KO and littermate control mice
underwent sham or MI surgery, and cardiac func-
tion was determined using serial 2-dimensional
motion-mode echocardiography at various time
points up to 8 weeks. Although post-MI infarct size,
hypertrophy, ﬁbrosis, and inﬂammation (as assessed
by nuclear factor kB activation) were comparable in
WT and KO mice (Online Figs. 1 to 4), ventricular
chamber dilation, both in systole and diastole, was
signiﬁcantly less in the KO mice, consistent with
reduced remodeling (Figs. 2A and 2B). The pre-
served chamber dimensions in the KO mice were
associated with signiﬁcantly better LV function, as
reﬂected by preserved ejection fraction and frac-
tional shortening (Figs. 2C and 2D). The smaller LV
internal dimension and the preserved cardiac
function in the KO mice were consistent and
remained signiﬁcantly better until the end of the
study (8 weeks post-MI). Although global Gsk3a
deletion leads to detrimental phenotypes due to
up-regulation of m-TORC1 (14,21), this was not the
case in the cardiac-speciﬁc conditional KO mice
(Online Figs. 5A to 5C). These observations suggest
that the inhibition of GSK-3a could be a novel
strategy to limit adverse ventricular remodeling and
dysfunction post-MI.
DELETION OF GsK3a ATTENUATES POST-MI
MYOCYTE DEATH AND SCAR EXPANSION. The
most striking ﬁnding in our studies was a marked
difference in scar expansion and content of the
scar. In the WT mice, the scar was markedly thin-
ned and comprised a much larger percent circum-
ference of the left ventricle than in the KO mice
(Figs. 3A to 3C and 3F). Furthermore, there werevery few viable myocytes within the scar area in the
WT mice. In contrast, the scar in the Gsk3a KO
mice’s hearts was much thicker and, importantly,
contained signiﬁcantly greater numbers of viable
cardiomyocytes (Figs. 3D and 3E). To determine the
mechanism of the increased thickness and reduced
scar circumference in the KO mice’s hearts, we per-
formed terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) staining using 3-week
post-MI heart sections. TUNEL-positive car-
diomyocytes were signiﬁcantly increased post-MI
irrespective of genotype. However, the number of
apoptotic cells was signiﬁcantly less in the hearts of
KO mice (Figs. 4A and 4B). The KO mice also showed
increased expression of the antiapoptotic factor
Bcl-2 and decreased expression of proapoptotic
Bcl-2-associated X (Bax) protein expression post-MI
(Figs. 4C and 4D). Thus, the ratio of Bax to Bcl-2,
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FIGURE 3 Better Preserved Wall Thickness and Reduced Scar Circumference in the Hearts of KO Mice
(A) Masson’s trichrome–stained images show sham, 3-week post–myocardial infarction (MI), and 8-week post-MI knockout (KO) and control
hearts. (B) Scar circumference was measured and expressed as a percentage of the total area of left ventricular (LV) myocardium. Scar
circumference and scar thickness were comparable in 3-week post-MI KO and wild-type (WT) mice (n ¼ 4 to 8 for WT and KO mice). (C) Scar
thickness measurement in both WT and KO mice revealed signiﬁcantly thicker and less expansive scar in 8-week post-MI KO mice’s hearts (n ¼ 8
to 13 for WT and KO mice). (D) Representative images of scars at higher magniﬁcation show thicker scar with increased numbers of viable
cardiomyocytes (red cells) in an 8-week post-MI KO mouse heart. (E) Quantiﬁcation of viable myocytes in the scar area revealed a signiﬁcantly
increased number in the KO mice’s hearts (n ¼ 7 hearts for each group). (F) Images of 8-week post-MI hearts from KO and littermate control
mice show less extensive and thicker scar in the KO mice. Results are expressed as mean  SEM. **p < 0.01; ***p < 0.0001.
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700an important indicator of caspase-3 activation and
apoptosis, was signiﬁcantly lower in the KO mice’s
hearts (Fig. 4D). These ﬁndings suggest that GSK-3a
promotes MI-induced cardiomyocyte death, which
leads to scar expansion and thinning and adverse
remodeling.DELETION OF Gsk3a PROMOTES POST-MI
CARDIOMYOCYTE PROLIFERATION. The increased
number of viable cardiomyocytes in the hearts of KO
mice also raised the possibility that deletion of Gsk3a
might drive cardiomyocyte proliferation. The role of
GSK-3a in cardiomyocyte proliferation post-MI is
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FIGURE 4 Gsk3a Deletion Attenuates Post-MI Cardiomyocyte Death
(A) Representative images show cardiomyocytes positive on terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) from the
wild-type (WT) and Gsk3a knockout (KO) hearts. (B) Quantiﬁcation shows signiﬁcantly decreased numbers of TUNEL-positive myocytes in
3-weeks post-MI KO mice’s left ventricles (n ¼ 4 for sham group and n ¼ 7 for MI group). (C) Representative immunoblot and (D) quantiﬁcation
show increased Bcl-2 expression, decreased expression of Bax, and decreased Bax/Bcl-2 ratio in the KO left ventricular (LV) lysates (n ¼ 4 to 5
for WT and KO mice). Values are mean  SEM. *p < 0.05; **p < 0.001.
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701unknown. To determine if GSK-3a regulates this
process, WT and KO animals were subjected to MI
surgery, and then 5-bromo-20-deoxyuridine (BrdU)
was injected starting from the third week and
continuing for 5 days. Immunostaining for BrdU
and the cardiomyocyte-speciﬁc marker troponin I
was performed using 3-week post-MI LV sections.
Only cells that were both BrdU and troponin I posi-
tive, with BrdU colocalizing with 4,6-diamidino-
2-phenylindole, were counted as proliferating
cardiomyocytes. Indeed, the number of proliferating
cardiomyocytes was signiﬁcantly increased in the
KO mice’s hearts (Figs. 5A and 5B). Immunostaining
for another deoxyribonucleic acid synthesis
marker, Ki67, also showed increased numbers of
Ki67-positive cardiomyocytes in the KO hearts
(Figs. 5C and 5D). To further investigate the role of
GSK-3a on MI-induced cardiomyocyte prolifera-
tion, the mitosis marker phospho-histone H3
(Ser10) was examined by immunostaining. Consistent
with the aforementioned ﬁndings, an increased
number of cardiomyocytes positive for phospho-
histone H3 were observed in the hearts of KO mice
(Figs. 5E and 5F). These results conﬁrm robust post-MI
cardiomyocyte proliferation in the KO mice’s heartsand suggest that GSK-3a is a potent regulator of
cardiomyocyte proliferation in the adult ischemic
heart.
Gsk3a DELETION PROMOTES POST-MI CYCLIN E1
AND E2F-1 RECRUITMENT. To determine how GSK-3a
might regulate cardiomyocyte proliferation, we
examined pro-proliferative factors that might be
responsible, including the Wnt/b-catenin pathway,
cyclin-dependent kinases, cyclins, and the E2F-1
transcription factor (Online Figs. 6A to 6C). From
this list, we identiﬁed 2 candidates, cyclin E1 and
E2F-1, in post-MI KO mice’s hearts. The protein
level of the transcription factor E2F-1 was signiﬁ-
cantly increased in the hearts of KO mice post-MI
(Figs. 6A and 6B). This was not regulated through
retinoblastoma protein (Rb), because phosphoryla-
tion (Ser780) of Rb was comparable between WT
and KO mice (Figs. 6A and 6B). To further dissect
molecular mechanisms responsible for GSK-3a-
mediated E2F-1 signaling, we examined the possi-
bility of direct interaction between these proteins
by immunoprecipitation assay using neonatal rat
ventricular myocyte lysates. We observed a strong
interaction between GSK-3a and E2F-1 (Fig. 6C),
suggesting that GSK-3a directly regulates E2F-1
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FIGURE 5 Deletion of Gsk3a Promotes Post-MI Cardiomyocyte Proliferation
(A) Representative images show 5-bromo-20-deoxyuridine (BrdU)–positive cardiomyocytes from the wild-type (WT) and Gsk3a–knockout
(KO) hearts. (B) Quantiﬁcation shows signiﬁcantly increased numbers of BrdU-positive myocytes in 3-week post–myocardial infarction
(MI) KO mice’s hearts (n ¼ 6 for each group). (C) Images show Ki67-positive cardiomyocytes. (D) Quantiﬁcation shows an increased
number of Ki67-positive cardiomyocytes in Gsk3a-KO hearts (n ¼ 4 to 5). (E) Representative images show phospho-histone H3
(p-H3) (Ser10)–positive myocytes in 3-week post-MI hearts. (F) Quantiﬁcation shows an increased number of p-H3-positive myocytes
in the KO mice’s hearts (n ¼ 4 for sham group and n ¼ 6 for MI group). Results are expressed as mean  SEM. **p < 0.01;
***p < 0.0001.
Ahmad et al. J A C C V O L . 6 4 , N O . 7 , 2 0 1 4
GSK-3a Regulates Post-MI Remodeling A U G U S T 1 9 , 2 0 1 4 : 6 9 6 – 7 0 6
702levels in cardiomyocytes independent of Rb
phosphorylation.
Cyclin E1 is an important G1-to-S transition-phase
marker and plays an important role in cell prolifer-
ation. A signiﬁcant up-regulation of cyclin E1 was
observed in the KO mice’s hearts post-MI (Figs. 7A
and 7B). To examine cyclin E1 speciﬁcally in car-
diomyocytes, immunostaining was performed on 3-
week post-MI heart sections. Only double-positive
cells with cyclin E1 and a-actinin (a cardiomyo-
cyte marker), with cyclin E1 colocalizing with4,6-diamidino-2-phenylindole, were counted as pro-
liferating cardiomyocytes. The number of cyclin E1–
positive cardiomyocytes was signiﬁcantly increased
in the KO mice (Figs. 7C and 7D). To study the
mechanism responsible for GSK-3a-mediated cyclin
E1 regulation, neonatal rat ventricular myocytes
were treated with the GSK-3 inhibitor SB216763 for
1.5 h, and cyclin E1 phosphorylation was determined.
Phosphorylation of cyclin E1 (Thr395) was signiﬁ-
cantly decreased by GSK-3 inhibition (Fig. 7E). To
determine if GSK-3a and cyclin E1 directly interact,
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703we performed co-immunoprecipitation assays using
cyclin E1 antibody, which suggested a direct
interaction between GSK-3a and cyclin E1. To
examine if this interaction is dependent on GSK-3a
kinase activity, co-immunoprecipitation assay was
performed in the presence of GSK-3 inhibitor
(SB216763). Indeed, the interaction between cyclin
E1 and GSK-3a was reduced in the presence of
GSK-3 inhibitor, as reﬂected by a lower level of
pull-down of GSK-3a (Fig. 7F). These data suggest
that GSK-3a directly interacts with and phosphor-
ylates cyclin E1 in cardiomyocytes. To our knowl-
edge, this is the ﬁrst report of direct regulation of
cyclin E1 by GSK-3a. Taken together, these ﬁnd-
ings suggest that deletion of GSK-3a promotes
post-MI E2F-1 and cyclin E1 recruitment and in-
duces the reentry of adult cardiomyocytes into the
cell cycle.(A) Representative immunoblots show phospho-Rb protein (pRb) (Ser790) and E2F-1
from 3-week post–myocardial infarction (MI) left ventricular (LV) lysates.
(B) Quantiﬁcation shows comparable pRb and signiﬁcantly increased levels of E2F-1 in
the post-MI knockout (KO) mice’s hearts (n ¼ 4 to 5). Results are expressed
as mean  SEM. **p < 0.01. (C) Co-immunoprecipitation using an antibody against
E2F-1 followed by immunoblotting for glycogen synthase kinase (GSK)–3a in
neonatal rat ventricular myocytes (NRVMs) conﬁrms a physical interaction between
these molecules.DISCUSSION
After an MI, the heart undergoes the process of
remodeling, which consists of LV dilation and con-
tractile dysfunction, often leading to heart failure.
Strategies to prevent remodeling largely center
around neurohormonal blockade (e.g., b-blockers and
angiotensin-converting enzyme inhibitors) and,
although beneﬁcial to some degree, often cannot
prevent heart failure in many patients, especially
those with larger infarcts. Herein, we identify the a
isoform of GSK-3 as a novel and potent promoter of
remodeling post-MI, in part driven by profound scar
expansion and leading to marked LV dysfunction.
In stark contrast, the deletion of GSK-3a leads to
much less dilative remodeling and better preserved
LV function. The diminished remodeling post-MI
in the KO mice is accompanied by a thicker scar
and markedly increased numbers of viable car-
diomyocytes within the scar area of KO mice’s hearts
compared with those of WT mice. The profound
reduction in ventricular dilation and scar expansion
in the KO mice was supported by both less apoptosis
and new myocyte formation post-MI (Central
Illustration).
The traditional strategy (e.g., total somatic
[global] gene deletion) can lead to secondary and
compensatory effects that greatly complicate the
interpretation of phenotypes (19). Global gene
deletion can result in embryonic lethality if the gene
is required for development. Moreover, global
deletion induces compensatory changes in other
genes as a means of preventing lethality. One of the
best examples is from the GSK-3 family (e.g., globaldeletion of Gsk3b is lethal because of hyper-
proliferation of cardiomyoblast and congenital heart
defects) (9). However, cardiac-speciﬁc conditional
deletion has no overt effect and is protective post-MI
in adults (11). Conversely, germline deletion of Gsk3a
does not affect the embryonic development and
pathophysiology of adult mice up to 4 months
post-birth but leads to functional deterioration
with aging (15,21). Given these complications of
global gene targeting, tissue-speciﬁc approaches
have become more widely adopted to bypass the
confounding phenotypes observe in global gene-
targeting strategies.
Both global deletion and constitutive activation
of GSK-3a, under a variety of stresses, have been
shown to induce detrimental phenotypes of cardiac
hypertrophy and remote ﬁbrosis (15,16). Moreover,
germline global deletion of Gsk3a has been shown to
induce progressive cardiac hypertrophy and contrac-
tile dysfunction, even in the absence of a cardiac-
speciﬁc stress (14,21). Importantly, our ﬁndings,
which show no hypertrophy or ﬁbrosis post-MI, pro-
vide a stark contrast to previous reports and suggest
that GSK-3a likely plays little or no direct role in
stress-induced cardiac hypertrophy and remote
ﬁbrosis. In summary, the previously reported role
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FIGURE 7 GSK-3a Regulates Post-MI Cyclin E1
(A) Immunoblot of left ventricular (LV) lysates and (B) quantiﬁcation show increased levels of cyclin E1 in 3-week post–myocardial infarction
(MI) Gsk3a knockout (KO) mice’s hearts (n ¼ 4 to 5). (C) Representative images show cyclin E1-positive cardiomyocytes in 3-week post-MI wild-
type (WT) and KO mice’s hearts. (D) Quantiﬁcation shows signiﬁcantly increased numbers of cyclin E1–positive cardiomyocytes in the post-MI
KO mice’s hearts (n ¼ 5 to 6 for WT and KO mice’s hearts). Results are expressed as mean  SEM. ***p < 0.0001. (E) Neonatal rat ventricular
myocytes (NRVMs) were exposed to the glycogen synthase kinase (GSK)–3 inhibitor SB216763 (10 mmol/l) for 1.5 h, followed by immuno-
blotting for phospho-cyclin E1 (Thr395). Immunoblot shows a low level of phosphorylation of cyclin E1 in drug-treated NRVMs in comparison
with control and vehicle-treated groups. (F) NRVMs were similarly treated with SB216763, and co-immunoprecipitation was performed using
lysate and antibody against cyclin E1, followed by immunoblotting for GSK-3a from co-immunoprecipitated protein. Blot shows a strong
interaction between GSK-3a and cyclin E1. However, in contrast, diminished binding was observed when the kinase activity of GSK-3a was
inhibited with SB216763.
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704of GSK-3a in various stress settings is likely due to
secondary effects of global gene deletion and/or
transgenesis.
Cardiomyocyte death, even at very low rates, can
lead to signiﬁcant collective loss of cardiomyocytes
over time and is reported to cause post-MI cardiac
dysfunction and heart failure (22). Our ﬁndings
show that GSK-3a is a potent promoter of car-
diomyocyte death and apoptosis in the ischemic
heart by inducing Bcl-2 and inhibiting Bax activity.
Bcl-2 is a known antiapoptotic factor (23) thatprotects against oxidative stress-induced apoptosis
and preserves cardiomyocyte viability and LV func-
tion in the ischemic heart when overexpressed (24).
Our ﬁndings suggest that cardiomyocyte-speciﬁc
deletion of Gsk3a leads to increased expression of
Bcl-2, and this limits cardiomyocyte death in chronic
MI.
We also report robust cardiomyocyte proliferation
in the Gsk3a-KO mice’s hearts, as evidenced by
increased Ki67- and BrdU-positive cardiomyocytes.
Mechanistically, we found that deletion of Gsk3a
CENTRAL ILLUSTRATION Schematic Representation Shows Pathogenesis
of Post-MI Cardiac Remodeling in the Gsk3a KO Heart
In resting cells, glycogen synthase kinase (GSK)–3a is in an active state, and
myocardial infarction (MI) leads to it inhibition. Deletion of GSK-3a in the car-
diomyocytes induces up-regulation of cyclin E1 and the E2F-1 transcription factor that
promotes cardiomyocyte proliferation post–MI. Cardiac-speciﬁc deletion of GSK-3a
also up-regulates Bcl-2 and down-regulates BAX expression post-MI, resulting in
attenuated myocyte apoptosis in the knockout (KO) hearts. Taken together, increased
myocyte proliferation and less apoptosis lead to profound cardiac protection, as
reﬂected by preserved left ventricular (LV) function and reduced ventricular
remodeling in the KO mice post-MI. LAD ¼ left anterior descending coronary
artery; RV ¼ right ventricle.
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705increases E2F-1 recruitment in the KO mice’s hearts
post-MI. Although a previous study showed that
GSK-3a regulates E2F through cyclin D1 post trans-
verse aortic constriction (16), we observed that
cyclin D1 played no role in the cardiomyocyte-
speciﬁc KO mice post-MI (Online Figs. 6A to 6C).
These observations suggest that GSK-3a might
regulate E2F-1 in a stress-dependent manner, as
cyclin D1 was involved in transverse aortic
constriction but not in MI. Several studies have
shown that activation of Rb regulates E2F-1 (25,26),
but this was not a mechanism in the present study,
as phosphorylation of Rb was comparable between
WT and KO mice. Furthermore, we found that GSK-
3a directly interacts with E2F-1 in cardiomyocytes.
These ﬁndings suggest that GSK-3a is a direct
regulator of E2F-1, independent of cyclin D1 and Rb.
Similarly, an increased level of the G1/S transition-
phase marker cyclin E1 was observed in the hearts
of KO mice. Our data suggest that GSK-3a phos-
phorylates and regulates cyclin E1 levels and
emphasize the fact that GSK-3a is a key and novel
regulator of cyclin E1 in the cardiomyocyte. The
elevated levels of E2F-1 and cyclin E1 in the KO
mice appear to be the central mechanism for car-
diomyocyte proliferation.
STUDY LIMITATIONS. Herein we propose that se-
lective inhibition of GSK-3a could signiﬁcantly
improve outcomes in patients with ischemic injury.
Selective inhibition of GSK-3a has not, to our
knowledge, been achieved with available drugs. In
fact, inhibition of GSK-3b can have adverse effects
on the heart. The ideal scenario would be to have a
compound that selectively inhibits GSK-3a (and not
the other isoform, GSK-3b). Eventually this hurdle
will be conquered and small molecules will be
developed that selectively target GSK-3a. These
agents could be very beneﬁcial in patients with
ischemic disease.
CONCLUSIONS
We present ﬁndings that reveal the potential trans-
lational value of GSK-3a inhibition in the setting
of chronic MI. Cardiomyocyte-speciﬁc conditional
deletion of Gsk3a preserves cardiac function, limits
ventricular remodeling, attenuates cardiomyocyte
death, restricts scar expansion and thinning, and
promotes cardiomyocyte proliferation post-MI.
Taken together, these observations suggest that se-
lective inhibition of GSK-3a could be a therapeutic
strategy to limit MI-induced cardiac remodeling and
heart failure.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Thomas Force, Temple University School of Medicine,
Center for Translational Medicine and Cardiology
Division, 3500 N. Broad Street, Philadelphia, Penn-
sylvania 19140. E-mail: thomas.l.force@vanderbilt.
edu.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
In mouse models of left ventricular function after MI,
genetic expression of GSK-3a is associated with more
severe ventricular dilatation, adverse remodeling, and
heart failure.
TRANSLATIONAL OUTLOOK: All currently available
GSK-3 inhibitors target both the a and b isoforms, but
the development of new drugs that speciﬁcally inhibit
GSK-3a could be promising for study in large animal
models of MI.
Ahmad et al. J A C C V O L . 6 4 , N O . 7 , 2 0 1 4
GSK-3a Regulates Post-MI Remodeling A U G U S T 1 9 , 2 0 1 4 : 6 9 6 – 7 0 6
706RE F E RENCE S1. Velagaleti RS, Pencina MJ, Murabito JM, et al.
Long-term trends in the incidence of heart failure
after myocardial infarction. Circulation 2008;118:
2057–62.
2. Kenneth DJX, Sherry LM, Arialdi MM, Hsiang-
Ching K. Death: preliminray data for 2009. Natl
Vit Stat Rep 2011;59:1–51.
3. Porrello ER, Mahmoud AI, Simpson E, et al.
Transient regenerative potential of the neonatal
mouse heart. Science 2011;331:1078–80.
4. Pasumarthi KB, Field LJ. Cardiomyocyte cell
cycle regulation. Circ Res 2002;90:1044–54.
5. Chiong M, Wang ZV, Pedrozo Z, et al. Car-
diomyocyte death: mechanisms and translational
implications. Cell Death Dis 2011;2:e244.
6. Bolli R, Chugh AR, D’Amario D, et al. Cardiac
stem cells in patients with ischaemic cardiomy-
opathy (SCIPIO): initial results of a randomised
phase 1 trial. Lancet 2011;378:1847–57.
7. Haq S, Michael A, Andreucci M, et al. Stabiliza-
tion of b-catenin by a Wnt-independent mecha-
nism regulates cardiomyocyte growth. Proc Nat
Acad Sci U S A 2003;100:4610–5.
8. Doble BW, Patel S, Wood GA, et al. Functional
redundancy of GSK-3alpha and GSK-3beta in Wnt/
beta-catenin signaling shown by using an allelic
series of embryonic stem cell lines. Dev Cell 2007;
12:957–71.
9. Kerkela R, Kockeritz L, Macaulay K, et al. Dele-
tion of GSK-3beta in mice leads to hypertrophic
cardiomyopathy secondary to cardiomyoblast hy-
perproliferation. J Clin Invest 2008;118:3609–18.
10. Doble BW, Woodgett JR. Exploring pluripo-
tency with chemical genetics. Cell Stem Cell
2009;4:98–100.11. Woulfe KC, Gao E, Lal H, et al. Glycogen syn-
thase kinase-3beta regulates post-myocardial
infarction remodeling and stress-induced car-
diomyocyte proliferation in vivo. Circ Res 2010;
106:1635–45.
12. Ruel L, Bourouis M, Heitzler P, et al.
Drosophila shaggy kinase and rat glycogen
synthase kinase-3 have conserved activities and
act downstream of Notch. Nature 1993;362:
557–60.
13. Siegfried E, Chou TB, Perrimon N. Wingless
signaling acts through zeste-white 3, the
Drosophila homolog of glycogen synthase kinase-
3, to regulate engrailed and establish cell fate. Cell
1992;71:1167–79.
14. Zhou J, Lal H, Chen X, et al. GSK-3alpha
directly regulates beta-adrenergic signaling and
the response of the heart to hemodynamic stress
in mice. J Clin Invest 2010;120:2280–91.
15. Lal H, Zhou J, Ahmad F, et al. Glycogen syn-
thase kinase-3alpha limits ischemic injury, cardiac
rupture, post-myocardial infarction remodeling
and death. Circulation 2012;125:65–75.
16. Matsuda T, Zhai P, Maejima Y, et al. Distinct
roles of GSK-3alpha and GSK-3beta phosphoryla-
tion in the heart under pressure overload. Proc
Natl Acad Sci U S A 2008;105:20900–5.
17. Zhai P, Gao S, Holle E, et al. Glycogen synthase
kinase-3alpha reduces cardiac growth and pres-
sure overload-induced cardiac hypertrophy by in-
hibition of extracellular signal-regulated kinases.
J Biol Chem 2007;282:33181–91.
18. Maejima Y, Galeotti J, Molkentin JD, et al.
Constitutively active MEK1 rescues cardiac dysfunc-
tion caused by overexpressed GSK-3alpha during
aging and hemodynamic pressure overload. Am J
Physiol Heart Circ Physiol 2012;303:H979–88.19. Davis J, Maillet M, Miano JM, Molkentin JD.
Lost in transgenesis: a user’s guide for genetically
manipulating the mouse in cardiac research. Circ
Res 2012;111:761–77.
20. Gao E, Lei YH, Shang X, et al. A novel and
efﬁcient model of coronary artery ligation and
myocardial infarction in the mouse. Circ Res 2010;
107:1445–53.
21. Zhou J, Freeman TA, Ahmad F, et al. GSK-3alpha
is a central regulator of age-related pathologies in
mice. J Clin Invest 2013;123:1821–32.
22. Kung G, Konstantinidis K, Kitsis RN. Pro-
grammed necrosis, not apoptosis, in the heart.
Circ Res 2011;108:1017–36.
23. Hockenbery DM, Oltval ZN, Yin XM, et al. Bcl-2
functions in an antioxidant pathway to prevent
apoptosis. Cell 1993;75:241–51.
24. Chatterjee S, Stewart AS, Bish LT, et al. Viral
gene transfer of the antiapoptotic factor Bcl-2
protects against chronic postischemic heart fail-
ure. Circulation 2002;106:I212–7.
25. Harbour JW, Dean DC. The Rb/E2F pathway:
expanding roles and emerging paradigms. Genes
Dev 2000;14:2393–409.
26. Nevins JR. E2F: a link between the Rb tumor
suppressor protein and viral oncoproteins. Science
1992;258:424–9.
KEY WORDS cardiomyocyte proliferation,
GSK-3a, heart failure, myocardial infarction,
ventricular remodeling
APPENDIX For a supplemental methods
section as well as ﬁgures, please see the
online version of this article.
